Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for Dominant-Negative GHR Mutation
NCT05382637Phase 2Active, not recruiting
- Sponsor
- Children's National Research Institute
- Start
- Aug 2022
- Primary completion
- Sep 2023
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of somatropin in growth hormone insensitivity syndrome (GHIS), sponsored by Children's National Research Institute. Primary endpoint: Growth Hormone Dose at 1 year. Started Aug 2022; status: active, not recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone insensitivity syndrome (GHIS)
Beyond the preview
Go deeper on NCT05382637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382637.